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AbsTrACT
background Spinocerebellar ataxia type 28 (Sca28) 
is a dominantly inherited neurodegenerative disease 
caused by pathogenic variants in AFG3L2. the aFg3l2 
protein is a subunit of mitochondrial m-aaa complexes 
involved in protein quality control. Objective of this study 
was to determine the molecular mechanisms of Sca28, 
which has eluded characterisation to date.
Methods We derived Sca28 patient fibroblasts carrying 
different pathogenic variants in the aFg3l2 proteolytic 
domain (missense: the newly identified p.F664S and 
p.M666t, p.g671r, p.Y689H and a truncating frameshift 
p.l556fs) and analysed multiple aspects of mitochondrial 
physiology. as reference of residual m-aaa activity, we 
included SPaX5 patient fibroblasts with homozygous 
p.Y616c pathogenic variant, AFG3L2+/− HeK293 t cells 
by criSPr/cas9-genome editing and Afg3l2−/− murine 
fibroblasts.
results We found that Sca28 cells carrying missense 
changes have normal levels of assembled m-aaa 
complexes, while the cells with a truncating pathogenic 
variant had only half of this amount. We disclosed 
inefficient mitochondrial fusion in Sca28 cells caused by 
increased OPa1 processing operated by hyperactivated 
OMa1. notably, we found altered mitochondrial 
proteostasis to be the trigger of OMa1 activation in 
Sca28 cells, with pharmacological attenuation of 
mitochondrial protein synthesis resulting in stabilised 
levels of OMa1 and OPa1 long forms, which rescued 
mitochondrial fusion efficiency. Secondary to altered 
mitochondrial morphology, mitochondrial calcium uptake 
resulted decreased in Sca28 cells.
Conclusion Our data identify the earliest events in 
Sca28 pathogenesis and open new perspectives for 
therapy. By identifying similar mitochondrial phenotypes 
between Sca28 cells and AFG3L2+/− cells, our results 
support haploinsufficiency as the mechanism for the 
studied pathogenic variants.
INTroduCTIoN
Spinocerebellar ataxias (SCAs) are a clinically and 
genetically heterogeneous group of autosomal 
dominant neurodegenerative disorders primarily 
characterised by progressive gait ataxia, imbal-
ance and dysarthria. Among the 46 different SCA 
subtypes identified to date (http:// neuromuscular. 
wustl. edu/ ataxia/ domatax. html), SCA type 28 
(SCA28; MIM #610246) is the only one caused 
by pathogenic variants in a resident mitochondrial 
protein, AFG3L2.1 The clinical spectrum of SCA28 
comprises slowly progressive gait and limb ataxia, 
and oculomotor abnormalities (eg, ophthalmopa-
resis and ptosis) as typical signs.2
AFG3L2 belongs to the AAA-protease subfamily 
(ATPases associated with various cellular activ-
ities) and assembles into homo-oligomers and 
hetero-oligomers with paraplegin in the inner mito-
chondrial membrane (IMM), named m-AAA prote-
ases. AFG3L1 is a third m-AAA paralogue subunit 
that is expressed in mouse, but not in humans due 
to a pseudogenisation event.3 AFG3L1 can also 
form homo-oligomers or hetero-oligomers, while 
paraplegin can only form hetero-oligomers. Based 
on the expression levels of each of the m-AAA 
subunits, different tissues will possess a peculiar 
cohort of these homo-oligomeric or hetero-oligo-
meric complexes.4
The m-AAA proteases are crucial component of 
the quality control system of the IMM and mediate 
the selective degradation of non-assembled and 
damaged proteins.5 Furthermore, they exert addi-
tional regulatory functions to promote mitochon-
drial protein synthesis,6 assembly of respiratory 
chain complexes,7 8 mitochondrial dynamics9 10 and 
mitochondrial calcium homeostasis.11 12
Most of the reported SCA28 pathogenic muta-
tions are heterozygous missense variants within the 
key proteolytic domain encoded by exons 15 and 16 
of AFG3L2.1 13–17 Even though the genetic variants 
are similar in type and location within AFG3L2, the 
clinical phenotype of SCA28 patients is associated 
with a wide range of symptoms severity and age of 
onset.2 Other variants have included one missense 
in exon 4,18 one missense in exon 10,1 a truncating 
frameshift in exon 1519 and a deletion spanning 
exons 14–16.20
In addition, a homozygous missense pathogenic 
variant in AFG3L2 in two brothers of a consanguin-
eous family has been shown to cause a different and 
more severe disease, spastic ataxia type 5 (SPAX5), 
characterised by early-onset spastic ataxia, neurop-
athy, ptosis, oculomotor apraxia, dystonia, cere-
bellar atrophy and progressive myoclonic epilepsy.21 
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Recently, the clinical phenotype associated to AFG3L2 patho-
genic variants has been further expanded by two reports of 
different homozygous pathogenic variants associated with 
progressive myoclonus epilepsy22 and refractory epilepsy with 
progressive microcephaly,23 respectively.
We provided evidence that Afg3l2+/− haploinsuffi-
cient mouse recapitulates most features of SCA28 patients, 
displaying defects in motor coordination and balance due to 
dark cell degeneration (DCD) of Purkinje cells (PCs).24 In this 
SCA28 model, DCD originates from increased cytoplasmic 
calcium concentrations ([Ca2+]c) because of inefficient trans-
port of mitochondria in PC dendrites.11 Similarities between 
human and mouse models of AFG3L2-related disorders also 
extend to Afg3l2−/− mice. These mice resemble patients with 
homozygous pathogenic variants by having a severe neurolog-
ical syndrome associated with ataxia and spasticity and early 
lethality at P16.8
These findings suggest that loss of function of the mutated 
protein is behind the pathogenesis of the human AFG3L2 vari-
ants (heterozygous for SCA28 and homozygous for SPAX5). 
However, since in Afg3l2+/− mouse the protein is reduced in 
amount rather than mutated, this model does not fully explain 
whether the reduced m-AAA complex activity in SCA28 is caused 
by haploinsufficiency or by a dominant negative effect exerted 
by the mutated protein on the wild-type (wt). Furthermore, the 
presence of the additional m-AAA protease subunit AFG3L1 in 
the mouse may be compensating for some of effects caused by 
the haploinsufficiency/absence of AFG3L2.
In order to clarify the pathogenic mechanism of SCA28, in 
this work, we characterised patient fibroblasts carrying different 
heterozygous missense or truncating frameshift pathogenic 
variants (the newly identified p.F664S, p.M666T, p.G671R, 
p.Y689H and p.L556fs). We found that the missense changes are 
similar to controls with regards to the total amount and ability 
of AFG3L2 to assemble into m-AAA complexes, while the trun-
cating frameshift variant is associated with half of this amount. 
Common phenotypic hallmarks of SCA28 cells were inefficient 
mitochondrial fusion and reduced mitochondrial calcium buff-
ering, while mitochondrial membrane potential (ΔΨm) was unaf-
fected. The altered mitochondrial morphology is the result of 
OMA1 hyperactivation causing increased processing and turn-
over of the long forms of OPA1. Of note, we demonstrated that 
the trigger for OMA1 hyperactivation in condition of reduced 
AFG3L2 activity is proteostatic stress due to the accumulation 
of mitochondria-encoded polypeptides. In agreement with these 
findings, we found that pharmacological attenuation of mito-
chondrial protein synthesis stabilised OMA1 activity with resto-
ration of OPA1 long forms and mitochondrial fusion in human 
SCA28 cells and Afg3l2−/−murine embryonic fibroblasts (MEFs). 
These results were replicated in AFG3L2+/− HEK 293 T cells 
generated by targeted genome editing. Taken together, our data 
provide new insights into the pathogenic cascade of SCA28 and 
identify a potential upstream target for therapy. Finally, different 
and complementary experimental findings indicate haploinsuf-




All patients or their legal representatives signed informed 
consent before enrolment.
Fibroblast derivation from skin biopsies
Patient-derived skin fibroblasts were obtained following standard 
procedures. Fibroblasts were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) medium supplemented with 20% Fetal 
Bovine Serum (FBS), 1 mM sodium piruvate, 2 mM L-glutamine 
and 100 U/mL penicillin-streptomycin. All cell culture reagents 
were from Thermo Fisher Scientific (Waltham, Massachusetts, 
USA). Seven SCA28 patient-derived fibroblast lines were used that 
included several previously reported SCA28 variants (p.M666T, 
p.G671R13 and p.Y689H15), and a partial deletion of exons 
14–16.20 A novel SCA28 variant (p.F664S) from a recently iden-
tified Italian family was also used, along with fibroblasts from a 
SPAX5 subject with a homozygous AFG3L2 variant (p.Y616C).21
Antibodies, drugs and reagents
Commercially available antibodies were used in western blots 
(WBs), for the detection of OPA1 and TIM44 (BD Transduction 
Laboratories, Franklin Lakes, New Jersey, USA), OMA1 (Novus 
Biologicals, Littleton, Colorado, USA), tubulin (DSHB, Univer-
sity of Colorado, Colorado, USA), HSP60 (Enzo Life Science, 
Farmingdale, New York, USA), MTCO1 and VDAC1 (Abcam, 
Cambridge, UK). Anti-AFG3L2 N-terminal (OriGene, Rock-
ville, Maryland, USA) and an anti-AFG3L2 C-terminal antibody 
(previously generated in the lab)7 were used to detect AFG3L2. 
Secondary antibodies used included Horseradish Peroxi-
dase (HRP)-conjugated antimouse and antirabbit IgG (Amersham 
Bioscience, Buckinghamshire, UK). Chloramphenicol succinate 
sodium salt (Merck, KGaA, Billerica, Massachusetts, USA) was 
used at a concentration of 200 µg/mL for 24 hours. Carbonyl 
cyanide-4 -(trifluoromethoxy)phenylhydrazone (FCCP) (Merck) 
was used at a concentration of 10 µM for 10 min.
Mitochondria isolation and blu-Native PAGe
Mitochondrial enrichments and Blu-Native PAGE (BN-PAGE) were 
performed as previously described8 followed by standard immuno-
blotting procedures.
Analysis of mitochondrial morphology
Primary skin fibroblasts (n=20 000) were plated on a bottom-
glass culture dishes (MatTek Corporation, Ashland, Massachu-
setts, USA) and infected with lentivirus expressing mitoDsRed2 
(Clontech, Mountain View, California, USA) (1:200 from 
4.67*108 U/mL). Seventy-two hours after infection, the mito-
chondrial network morphology was evaluated with live imaging 
using an Axio Observer.Z1 inverted microscope (Zeiss). On 
average, at least 100 cells/cell line were evaluated per experi-
ment. Three independent operators performed blinded analysis 
of the collected images.
Generation of monoclonal AFG3L2+/− heK 293 T cells by 
CrIsPr/Cas9-based technology
A 20 bp targeting sequence for spCas9 was selected in the 
coding sequence of exon 1 of AFG3L2 by using NCBI BLAST 
(https:// blast. ncbi. nlm. nih. gov/ Blast. cgi.). Candidate sequences 
with off-targets with up to two mismatches were excluded 
(GRCh38/hg38 was used as assembly reference). Comple-
mentary oligonucleotides (AFG3L2 FWD 5′ gatcg CTCCTC-
GTGCCTGGCGGCGTg 3′ and AFG3L2 REV 5′ aaaac 
ACGCCGCCAGGCACGAGGAGc 3′) for gRNA were annealed 
and cloned into BamHI and BsmBI sites of pCas-Guide-EF1a-GFP 
CRISPR/Cas9 All-in-One vector (GE10018, OriGene). HEK 
293 T cells were transfected with the pCas-Guide-EF1a-GFP 
vector containing the AFG3L2 targeting sequence, and 48 hours 








enet: first published as 10.1136/jm





3Tulli S, et al. J Med Genet 2019;0:1–13. doi:10.1136/jmedgenet-2018-105766
Neurogenetics
after transfection, Green Fluorescent Protein (GFP)-positive cells 
were sorted through fluorescence-activated cell sorting. Sorting 
was performed with FACSAria Fusion instrument and FACSDiva 
8.0 software (BD). Positive cells were collected into a 96 multi-
well plate. After 24 hours, cells were resuspended, and single 
cells were isolated by serial dilutions. Wells with single colonies 
were checked at the microscope, and monoclonal cell lines were 
expanded. Genomic DNA from monoclonal cells was amplified 
by PCR (primers: FWD 5′CCGCGTTGAGAGCTTGGG3′ and 
REV 5′ACCTTGACGTCCGCTCTC3′), and products were 
Sanger-sequenced to identify AFG3L2 heterozygous clones. WB 
analysis was then performed to verify the reduction of AFG3L2 
protein by 50%.
The clones used in this study are: clone #1 (allele1: p.R28fs; 
allele 2: p.G26del) and clone #2 (allele1: p.A14fs; allele 2: 
p.G27_V28del). The p.G26del and p.G27_V28del in frame 
deletions are located upstream of the leader peptide-cleavage site 
by mitochondrial matrix peptidase and therefore do not affect 
the mature AFG3L2.
Mitochondrial membrane potential evaluation
ΔΨm was measured using the mitochondrial potentiometric dye 
tetramethylrhodamine methyl ester (TMRM) (Invitrogen) and 
cytofluorimetric analysis as previously described.10 Physical 
parameters settings were specific for each cell line and data were 
reported as ratio between  TMRM/(TMRM+FCCP).
In vitro pulse labelling of mitochondrial translation products
Cells were incubated for 3.5 hours in methionine-free and cyste-
ine-free DMEM supplemented with 250 µg/mL of the cyto-
plasmic translation inhibitor cycloheximide and 10% dialysed 
FBS. They were then labelled with 35S-methionine/cysteine 
(0.22 mCi/plate) for 30 min and then harvested or chased 
(DMEM supplemented with 10% FBS) for 2 or 4 hours. For 
each condition, 30 µg of proteins were electrophoresed through 
a 10%–20% denaturing gel. Proteins were transferred to nitro-
cellulose membranes before autoradiography and sequentially 
probed with antibodies (anti-OMA1 and anti-VDAC1). To 
evaluate the efficacy of chloramphenicol in stabilising OMA1 
activity, cells were incubated for 24 hours with chloramphenicol 
before pulse labelling.
Cytosolic and mitochondrial calcium evaluation
Measurement of [Ca2+]c was performed as previously described.
25 
To quantify mitochondrial calcium responses ([Ca2+]m), fibro-
blasts were transfected with plasmid 4mtD126 and imaged 
48 hours after transfection as reported.11
statistical analysis
Continuous variables were summarised by their mean values 
and SEM; categorical variables were summarised by means of 
frequencies and percentages.
To evaluate possible differences in protein levels between 
patients and controls, densitometric analysis of WB bands 
from at least three independent experiments was performed 
using Image J ( imagej. nih. gov/ ij/ index. html), followed by 
Student’s t-test analysis. Differences in mitochondrial network 
morphology were calculated by χ2 analysis, using two df. To 
investigate differences in ΔΨm between patients and controls, 
and thus differences in the mean values of [(TMRM-Basal)]/
[(TMRM+FCCP)-Basal] among the groups (=‘kindof ’), we 
fitted a generalised linear model with nested random effect by 
means of penalised quasi-likelihood method taking into account 
the dependencies between measurements coming from the trip-
licates of the same cell line.27
resulTs
Missense AFG3L2 variants do not alter AFG3l2 monomer 
stability or m-AAA assembly
We derived primary fibroblasts from skin biopsies from seven 
different SCA28 patients. Some of the analysed pathogenic 
variants were already reported (p.M666T, p.G671R,13 a partial 
deletion of exons 14–16,20 p.Y689H15), while we identified 
p.F664S as a new SCA28-causing pathogenic variant in an Italian 
family. We also included in the study the only living SPAX5 
patient, carrying the homozygous AFG3L2 p.Y616C pathogenic 
variant.21
We first sequenced the cDNA of SCA28 patients carrying the 
C-terminal deletion, and we defined the pathogenic variant as a 
frameshift (p.L556fs) occurring in the end of exon 13, resulting 
in a premature stop codon (online supplementary figure S1A and 
S1B).
The clinical features of the analysed SCA28 patients are 
reported in table 1. The primary phenotype consisted of gait–
limb ataxia and dysarthria for all patients, with variability in 
the severity of symptoms and age of onset. The patient with the 
p.Y689H pathogenic variant has a milder phenotype with less 
severe gait–limb ataxia and no oculomotor or extrapyramidal 
signs.
The analysed pathogenic variants are all localised in the key 
metallopeptidase domain of AFG3L2 (online supplementary 
figure S2A). In silico analysis (PolyPhen-228 and SIFT29 tools) 
showed that all the SCA28 missense pathogenic variants anal-
ysed in this study are predicted to damage AFG3L2 function. 
Moreover, multiple species alignment shows that mutated resi-
dues are highly conserved through evolution (online supplemen-
tary figure S2B).





exam Gait ataxia limb ataxia dysarthria Nystagmus ophthalmo
Increased 
reflexes in ll Ptosis
MrI years at 
exam
M666T F 23 50 ++ + + + ++ – – CA and VA: 56.
F664S (p1) M 34 39 + + – + – + – Mild CA: 37.
F664S (p2) F 30 65 +++ +++ ++ NA NA NA – NA
G671R M 40 64 +++ +++ + – ++ ++ ++ CA and VA: 60.
L556fs (p1) M 36 49 ++ ++ ++ ++ ++ ++ ++ CA: 46; VA: 48.
L556fs (p2) M 35 54 ++ ++ ++ – ++ ++ – CA: 36; VA: 53.
Y689H M 43 60 ++ + ++ – – – – N
Symbols: +,present and mild; ++, present and moderate; +++, present and severe; −, absent; CA, cerebellar atrophy; LL, lower limbs; NA, not available; , ; VA, vermis atrophy.
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We analysed by WB the effect of the pathogenic variants on 
the stability of AFG3L2 monomer. The heterozygous missense 
pathogenic variants expressed similar total amount of full-length 
AFG3L2 protein as compared with controls (figure 1A). In 
contrast, this amount was decreased by ~50% in the p.L556fs 
fibroblasts (figure 1A). In these cells, the mutated allele is 
predicted to encode for a truncated protein of approximately 
62 kDa. In order to quantify the amount AFG3L2-p.L556fs 
protein relative to the full-length protein, we employed two 
different antibodies recognising either N-terminal or C-terminal 
epitopes of AFG3L2. In experiments with both antibodies, we 
observed that the truncated AFG3L2-p.L556fs has dramatically 
reduced expression compared with the wt protein (almost 20% 
relative to the full-length) (figure 1B and online supplemen-
tary figure S2C). Treatment with MG132 for the inhibition of 
proteasomal activity did not rescue truncated AFG3L2-p.L556fs 
protein in patient cells (online supplementary figure S2D), 
suggesting that this mutant is either degraded inside the mito-
chondria after being imported or its mRNA is unstable.
To verify if AFG3L2 pathogenic variants impact on the ability 
of the encoded protein to assemble into m-AAA complexes, we 
performed BN-PAGE on mitochondrial extracts (figure 1C). 
Fibroblasts carrying missense pathogenic variants had similar 
amounts of assembled m-AAA complexes, while these levels 
were decreased by ~50% with p.L556fs cells, demonstrating 
that the p.L556fs pathogenic variant causes a functional haplo-
insufficiency. Indeed, BN-PAGE followed by second dimension 
SDS-PAGE identified only full-length AFG3L2 in assembled 
m-AAA complex, indicating that the truncated AFG3L2-p.
L556fs protein is unable to oligomerise (online supplementary 
figure S3A and B). Cells with homozygous p.Y616C pathogenic 
variant were also shown to have similar amounts of AFG3L2 
protein, as both a monomer and assembled m-AAA complexes 
compared with controls (figure 1D and E).
Altered mitochondrial morphology in sCA28 patient 
fibroblasts
We and others have reported increased mitochondrial fragmen-
tation in Afg3l2−/−MEFs and primary PCs.9–11 To evaluate if 
mutated AFG3L2 affects mitochondrial morphology, we anal-
ysed the mitochondrial network in primary SCA28 patient fibro-
blasts by live imaging microscopy. While control cells possessed 
a highly fused and interconnected mitochondrial network, most 
of the SCA28 cells (and SPAX5 cells) had shorter and less inter-
connected organelles with more numerous mitochondrial units 
(figure 2A). Only the p.Y689H fibroblasts were not statistically 
different compared with controls in this regard.
To understand the molecular basis of this mitochondrial 
morphology defect, we analysed by WB the total protein amount, 
as well as post-translational processing of the pro-fusion protein 
OPA1. At steady state, the eight splicing variants of OPA1 
undergo constitutive processing at site 1 by OMA1-operated 
cleavage and/or at site 2 by YME1L-operated cleavage, leading 
to the accumulation of long (non-cleaved) and short forms. 
The OPA1 long forms have been demonstrated to be the active 
mediators of IMM fusion.30 31 We and others have previously 
shown that the absence of AFG3L2 destabilises OPA1 long forms 
compared with controls, leading to inhibition of mitochon-
drial fusion and mitochondrial network fragmentation.9 10 We 
observed SCA28 fibroblasts with mutated AFG3L2 have a signif-
icant reduction in the total amount of OPA1 (figure 2B and C). 
This phenotype is not the result of decreased mitochondrial mass 
or transcriptional downregulation (online supplementary figure 
S4A and B) but is likely due to faster processing and degrada-
tion of OPA1 in the presence of the AFG3L2 mutants. Of note, 
fibroblasts with the p.Y689H variant had reduced levels of OPA1 
long forms but was not as significant compared with cells with 
other pathogenic variants (figure 2B). This could explain their 
unaltered mitochondrial morphology.
The comparable phenotypes (altered mitochondrial morphology 
and OPA1 processing) seen with p.L556fs fibroblasts and 
missense-carrying cells suggest haploinsufficiency as the cause of 
SCA28 instead of dominant negative mechanism. To prove it, we 
used CRISPR/Cas9-mediated editing to generate AFG3L2 haplo-
insufficient HEK 293 T cells. These AFG3L2+/− cells also had the 
same reduction of OPA1 protein amount observed in the SCA28 
patient-derived cells (figure 2D: clone #1 and online supplemen-
tary figure S4D and E: clone #2), indicating that 50% reduction 
in m-AAA is capable of increasing OPA1 processing and alters 
mitochondrial morphology. Furthermore, the overexpression 
of the missense variants AFG3L2-p.F664S, AFG3L2-p.M666T 
or AFG3L2-p.G671R in Afg3l2−/− MEFs did not recover mito-
chondrial fragmentation even partially, indicating that these 
variants have no residual activity. By contrast, the coexpression 
of wt AFG3L2 with AFG3L2-p.F664S, AFG3L2-p.M666T or 
AFG3L2-p.G671R restored mitochondrial tubulation in Afg3l2−/− 
MEFs (online supplementary figure S4F), further indicating 
haploinsufficiency being the disease-causing mechanism for these 
variants.
Proteostatic stress in the IMM activates oMA1 in sCA28 cells
OMA1 has been shown to increase OPA1 cleavage in the absence 
of AFG3L2.9 In physiological conditions, OMA1 is a constitutively 
active protease, but it becomes hyperactivated in response to mito-
chondrial depolarisation and undergoes autocatalytic degrada-
tion.32 Although the link between the loss of AFG3L2 and OPA1 
processing is well established,9 10 the OMA1-related mechanisms 
triggering the increased processing of OPA1 in this setting are 
unknown. Therefore, we measured endogenous OMA1 levels in 
patient-derived SCA28 and SPAX5 cells and found a significant 
reduction in OMA1 protein compared with controls (figure 3A). 
This result was not due to a change in OMA1 transcriptional 
levels (online supplementary figure S4C), which indicates that 
OMA1 becomes hyperactivated (and thus highly autocatalysed) 
when AFG3L2 activity is reduced, leading to excessive processing 
of OPA1 long forms. The collapse of ΔΨm is the major stimulus 
that induces OMA1-mediated processing of OPA1.32 However, 
ΔΨm was maintained in SCA28 and SPAX5 cells, as measured 
by cytofluorimetric evaluation of the steady-state loading of the 
potentiometric dye tetramethylrhodamine methyl ester (TMRM) 
(figure 3B). This suggests a different stimulus being responsible 
for OMA1 activation in this setting of reduced AFG3L2 activity. 
Recent data point to a role for AFG3L2 in regulating the stability 
of mitochondria-encoded proteins in the IMM.33–35 Therefore, we 
performed pulse-chase experiments, which revealed the accumu-
lation of mitochondrial translation products in Afg3l2−/− MEFs 
compared with controls (figure 3C). After 2 hours and 4 hours 
of chase, we observed specific mitochondria-encoded polypep-
tides having a higher stability in Afg3l2−/− MEFs versus controls 
(ie, ND1, ND4, ND6 and ND4L/ATP8), with OMA1 levels 
decreasing proportionally with this stabilisation (figure 3C). To 
prove that the accumulation of mitochondria-encoded polypep-
tides was the stimulus for OMA1 activation, we treated p.L556fs 
cells, Afg3l2−/− MEFs, AFG3L2+/− HEK 293 T cells and human 
fibroblasts knockdown for AFG3L2 with chloramphenicol, an 
inhibitor of mitochondrial protein synthesis. Interestingly, in all 
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Figure 1 Missense pathogenic AFG3L2 variants do not alter the amount of m-aaa complexes. (a) WB analysis of fibroblast cell lysates showing 
levels of aFg3l2 in controls and patients with relative quantification. Bars represent means±SeM of three independent experiments. Student’s t-test: 
*p<0.05. (B) WB analysis showing residual levels of p.l556fs aFg3l2 (§) encoded by the mutant allele (boxed) using antibodies recognising an epitope 
on the n-terminus (left) or on the c-terminus of aFg3l2 (right), respectively. (c) Bn-Page of mitochondrial extracts from Sca28 fibroblasts and controls 
stained with anti-aFg3l2 and anti-HSP60 as loading control. Bars represent means±SeM of four independent experiments. Student’s t-test: **p<0.01. 
(D) WB analysis of fibroblast cell lysates from SPaX5 patient and controls showing levels of aFg3l2 monomer with relative quantification. Bars represent 
means±SeM of three independent experiments. (e) Bn-Page on mitochondrial extracts from SPaX5 fibroblasts and controls revealed with anti-aFg3l2 and 
anti-HSP60 as normaliser. Bars represent means±SeM of four independent experiments. WB, western blot.








enet: first published as 10.1136/jm





6 Tulli S, et al. J Med Genet 2019;0:1–13. doi:10.1136/jmedgenet-2018-105766
Neurogenetics
Figure 2 Mitochondrial fragmentation due to enhanced OPa1 processing and turnover in Sca28 fibroblasts. (a) representative images of mitochondrial 
morphology in Sca28 and SPaX5 primary fibroblasts infected with mtDsred2 and visualised by live imaging microscopy. the graph shows the morphometric 
analysis of mitochondrial morphology in Sca28 and SPaX5 primary fibroblasts. One hundred randomly selected cells were analysed on average in each 
experiment. Bars represent means±SeM of three independent experiments. χ2 test (2 df): controls (mean of 7 different lines) versus different pathogenic 
variants: ***p<0.0001. (B and c) WB of fibroblast cell lysates showing levels of OPa1 in controls and patients with relative quantifications (# highlights a 
non-specific band). Magnification of two independent anti-OPa1 immunoblots shows the OPa1-band pattern in Sca28-p.Y689H cells, with higher amount 
of OPa1 long forms and decreased OPa1 short forms (arrows) compared with Sca28-p.l556fs cells. Bars represent means±SeM of four independent 
experiments. Student’s t-test: *p<0.05 and **p<0.01. (D) WB of criSPr/cas9-engineered AFG3L2+/− HeK 293 t cells (clone #1) and controls showing levels 
of aFg3l2 and OPa1 with relative quantifications. aFg3l2 protein is reduced by 50% in AFG3L2+/− HeK 293 t cells and migrates at the same molecular 
weight compared with the wt controls, indicating that it is imported and undergoes correct maturation inside mitochondria. Bars represent means±SeM of 
four independent experiments. Student’s t-test: *p<0.05. Sca28, spinocerebellar ataxia type 28; wt, wild-type.
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Figure 3 OMa1 is activated by accumulation of mitochondria-encoded polypeptides in AFG3L2-mutated and depleted cells. (a) WB of fibroblast cell 
lysates from control and AFG3L2 patients showing levels of OMa1 in controls and patients with relative quantifications. Bars represent means±SeM of three 
independent experiments. Student’s t-test: *p<0.05; **p<0.01. (B) analysis of ΔΨm by cytofluorimetric evaluation of the potentiometric dye tMrM. Data 
are reported as the ratio between tMrM/(tMrM+FccP). Bars represent means±SeM of at least three independent experiments. (c) autoradiogram and 
WB analysis of the same membrane probed with antibodies directed against OMa1 and VDac1 (loading control). in this experiment, Afg3l2−/− MeFs and 
controls were pulse-labelled with 35S-methionine/cysteine for 30 min and harvested or chased for 2 or 4 hours. WB, western blot.
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cases we observed a complete rescue of OPA1 long forms, which 
correlated with the stabilisation of OMA1 levels (figure 4A and 
online supplementary figure S5A–D). Of note, the restored OPA1 
long form levels were associated with a recovery of mitochondrial 
network morphology in both SCA28 cells and Afg3l2−/− MEFs 
(figure 4B). As further evidence of this mechanism, we treated 
Afg3l2−/− MEFs for 24 hours with chloramphenicol and then 
performed pulse-chase experiments of mitochondrial translation 
products. Interestingly, in this setting, OMA1 protein levels were 
found to be stabilised immediately after pulse phase, but progres-
sively decreased during the chase phase because of the reactiva-
tion of mitochondrial protein synthesis (figure 4C). In addition, 
we demonstrated that the efficacy of chloramphenicol in main-
taining OPA1 long forms lasted for over 48 hours after treatment 
in Afg3l2−/− MEFs (online supplementary figure S6A–C).
reduced mitochondrial calcium uptake in sCA28 patient 
fibroblasts
We previously reported that Afg3l2−/− MEFs and primary PCs 
show a reduction in evoked mitochondrial calcium rises.10 11 
Recently, this defect was reported also in HeLa cells lacking 
the m-AAA complex.12 In Afg3l2+/−  mouse model, defective 
calcium handling was shown to alter calcium homeostasis in 
PCs, which led to DCD. This mechanism represents a crucial 
step in disease pathogenesis, therefore we assayed whether this 
defect was present in SCA28 and SPAX5 patient fibroblasts. To 
exclude differences in global cellular calcium signalling, [Ca2+]c 
was evaluated in patient cells and compared with controls. To 
this end, we performed fura-2 measurement of cytosolic calcium 
response after histamine stimulation, which leads to an inositol 
(1,4,5) triphosphate-triggered release of calcium from the ER 
stores. This analysis revealed no significant differences between 
SCA28 cells and controls (figure 5A). We then measured [Ca2+]m 
using a mitochondria-targeted version of the fluorescence reso-
nance energy transfer-based calcium probe 4mtD1cpv.26On chal-
lenge with 100 µM histamine, mitochondrial calcium rises were 
significantly smaller in SCA28 patient cells as compared with 
controls (figure 5B,C).
dIsCussIoN
In this study, we examined the pathogenic mechanisms under-
lying SCA28 by analysing a panel of patient-derived primary 
fibroblasts with different AFG3L2 pathogenic variants. These 
included several missense (p.M666T, p.G671R, p.Y689H and 
the newly identified p.F664S) and frameshift (p.L556fs) vari-
ants. We assayed in these SCA28 fibroblasts all the functional 
aspects of mitochondrial physiology that so far have been 
linked to m-AAA activity (ie, mitochondrial morphology, OPA1 
processing, OMA1 activation, mitochondrial protein synthesis, 
ΔΨm and calcium buffering). By comparing SCA28 fibroblasts 
with cells with reduced m-AAA activity (SPAX5 patient fibro-
blasts carrying the homozygous p.Y616C pathogenic variant, 
AFG3L2+/− HEK293 T cells generated by CRISPR/Cas9 genome 
editing and Afg3l2−/− MEFs) in regard of these phenotypes, 
our data indicate haploinsufficiency as the primary pathogenic 
mechanism in these SCA28 cells as opposed to a dominant nega-
tive process. Also, our findings identified the earliest steps in 
SCA28 pathogenic cascade, which may provide valuable targets 
for future therapy.
We demonstrated that p.L556fs fibroblasts possessed half of 
the amount of assembled m-AAA complexes (1MDa) compared 
with controls, being therefore functionally haploinsufficient. In 
contrast, cells from subjects with missense variants had similar 
steady-state levels of AFG3L2 monomers and assembled m-AAA 
complexes compared with controls. Interestingly, almost all 
AFG3L2 pathogenic variants we studied had similar mitochon-
drial phenotypes regardless of the total amount of AFG3L2 
monomers or assembled m-AAA complexes. These phenotypes 
included altered mitochondrial morphology associated with 
increased processing of OPA1 long forms by hyperactive OMA1. 
These results indicated that inefficient mitochondrial fusion is an 
important cause of AFG3L2-related pathogenesis. Of note, the 
only cells that did not have significantly reduced levels of OPA1 
long forms and altered mitochondrial network morphology 
were derived from a subject (p.Y689H) with a milder clinical 
phenotype compared with the other SCA28 patients. These data 
may indicate that OPA1-mediated mitochondrial fragmenta-
tion could be a cellular phenotype that correlates with disease 
severity.
We also measured mitochondrial calcium uptake in SCA28 
and SPAX5 cell lines because it was previously demonstrated 
to be the trigger of PC-DCD in the Afg3l2 haploinsufficient 
mouse.11 We found it reduced in SCA28 and SPAX5 cells, even 
though ΔΨm was unchanged. This result demonstrates that faulty 
mitochondrial calcium uptake could play a crucial role in SCA28 
cellular pathogenesis and that it is likely a consequence of altered 
mitochondrial morphology, as cells with the p.Y689H patho-
genic variants do not have any significant changes with these 
two parameters.
Mitochondrial abnormalities are seen to comparable extent in 
cells expressing missense changes or in the haploinsufficient ones, 
indicating that a dominant negative effect is unlikely. Indeed, if 
a dominant negative effect was the cause of the pathology, we 
would expect the overall activity of the m-AAA complexes to be 
more severely compromised than what we see with our missense 
and truncated mutants. Our data indicate that the missense vari-
ants we have studied are heterozygous loss of function variants 
that reduce m-AAA complexes functionality. Indeed, when over-
expressed in a null Afg3l2 background, they failed to recover 
mitochondrial fragmentation, not even partially.
The extent of m-AAA complexes reduction is however hard 
to be precisely quantified. This is because it depends on the 
stoichiometry of individual subunit types in homo-oligomeric 
m-AAA complexes composed of AFG3L2 and in hetero-oligo-
meric m-AAA complexes composed of AFG3L2 and paraplegin. 
Studies have demonstrated that m-AAA proteases are organ-
ised in hexamers,36 but how AFG3L2 and paraplegin subunits 
assemble in the m-AAA complexes, in terms of relative amount 
and reciprocal disposition, has not been clarified yet, even 
though it is known to be influenced by the relative abundance 
of subunits in distinct tissue types.4 Therefore, depending on the 
ratio between wt and mutated AFG3L2 subunits in homo-oligo-
meric complexes, as well as between wt and mutated AFG3L2 
subunits with paraplegin in hetero-oligomeric complexes, 
we hypothesise that a gradient of reduced activity of m-AAA 
complexes occurs in SCA28. Further evidence was provided with 
AFG3L2+/− HEK 293 T cells, wherein two different clones had 
AFG3L2 protein reduced by 50%. These cells also had decreased 
levels of OPA1 long forms and OMA1 as seen in patient cells. 
This result, together with AFG3L2 truncating and missense 
pathogenic variants expressing similar effects on mitochondrial 
physiology, indicate the overall residual activity of the m-AAA 
should be around 50% or more, consistent with haploinsuffi-
cient mechanism. Although strongly supported by our functional 
data, a haploinsufficient mechanism is not in agreement with the 
higher than expected frequency of AFG3L2 loss of function vari-
ants in ExAC database (http:// exac. broadinstitute. org). Many 
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Figure 4 rescue of OPa1 long forms and mitochondrial fragmentation by inhibition of mitochondrial protein synthesis in AFG3L2-mutated and depleted 
cells. (a) WB of fibroblast cell lysates showing levels of OPa1 and OMa1 in cells of the indicated genotype with or without chloramphenicol treatment. 
tiM44 was used to verify equal loading, and MtcO1 was used to verify inhibition of mitochondrial protein synthesis by chloramphenicol. FccP was used 
to verify OMa1 activation. * represents the cross reactivity of anti-aFg3l2 antibody with murine aFg3l1 in mouse cells. (B) representative pictures 
of mitochondrial morphology in Sca28-p.l556fs primary fibroblasts and Afg3l2−/− MeFs in normal conditions and on chloramphenicol treatment. (c) 
autoradiogram and WB analysis of the same membrane probed with antibodies directed against OMa1 and VDac1 (loading control). in this experiment, 
Afg3l2−/− MeFs and controls were treated with chloramphenicol for 24 hours and then pulse-labelled with 35S-methionine/cysteine for 30 min and harvested 
or chased for 2 or 4 hours. MeFs, murine embryonic fibroblasts; Sca28, spinocerebellar ataxia type 28; WB, western blot.
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explanations, such as bias in sequencing, CNVs, as well as the 
age of individuals (ie, sequencing was done prior to the onset of 
symptoms in the late-onset disorder) and clinical misdiagnosis 
may account for this discrepancy. Indeed, SCA28 is a mild and 
slowly progressing form of ataxia, frequently underdiagnosed. 
Of note, all the pathogenic variants that we analysed in this study 
are located within the proteolytic domain of AFG3L2; therefore, 
we can only comment on these types of mutations and cannot 
exclude that variants located in other AFG3L2 domains may act 
through a dominant negative effect. The p.Y689H variant had 
a milder cellular phenotype compared with the other missense 
variants. We may speculate that the p.Y689 residue, being located 
almost 20 aminoacids downstream the other studied variants, 
affects the proteolytic activity of AFG3L2 in some milder form.
We included in this study fibroblasts from a SPAX5 patient 
carrying the AFG3L2 homozygous recessive variant p.Y616C. 
At the mitochondrial level, the phenotype of SPAX5 cells were 
comparable with those of SCA28 and AFG3L2+/− HEK 293 T 
cells but markedly milder compared with Afg3l2−/− MEFs. These 
data suggest that the p.Y616C mutant is a pathogenic hypomorph 
and is not a complete loss of function variant, and so requires 
both alleles to be affected to cause AFG3L2-related disease. 
This is also consistent with the asymptomatic status of both the 
heterozygous parents of this SPAX5 patient,21 although they may 
be presymptomatic. However, this hypothesis is in contrast with 
the very severe neurological phenotype of the SPAX5 patient.21 
One explanation could be that in the different neuronal popula-
tions affected in SPAX5, the homozygous p.Y616C pathogenic 
variant causes a more severe phenotype compared with fibro-
blasts. We should also consider that other genes may contribute/
modify the clinical phenotype in this consanguineous pedigree.
We found abnormal mitochondrial morphology as a unifying 
element of both SCA28 and SPAX5 pathogenesis. In both disor-
ders, cells lose the highly tubulated and interconnected mito-
chondrial network as a result of decreased levels of OPA1 long 
forms, which is essential for efficient fusion of the IMM.30 31 
While it has been previously shown that OMA1 is the protease 
mediating increased OPA1 processing in the absence of AFG3L2,9 
Figure 5 Decreased mitochondrial calcium uptake in Sca28 fibroblasts. (a) Means±SeM of [ca2+]c (peak responses) after histamine stimulation evaluated 
by the fura-2 fluorescence 340/380 ratio (fold increase above the basal value; n=3–5 for each cell line, an average of 15 traces analysed/experiment). (B) 
Means±SeM of [ca2+]m (peak responses) after histamine stimulation (normalised increase in YFP/cFP ratio measured above the initial value; n=5, from 5 
to 10 traces analysed/experiment). Student’s t-test: *p<0.05. (c) representative traces of evoked mitochondrial calcium responses in Sca28 and SPaX5 
fibroblasts expressing 4mtD1cpv. traces from different cell lines have been shifted along the time-axis for clarity. Sca28, spinocerebellar ataxia type 28; 
SPaX5, spastic ataxia type 5.
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the detection of activated OMA1 in condition of absence/patho-
genic variant of AFG3L2 or the stimuli that trigger this activa-
tion remains elusive.
We found that OMA1 has increased activation in SCA28 and 
SPAX5 cells, as well as in AFG3L2+/− HEK 293 T cells, in human 
fibroblasts treated with AFG3L2 siRNA and in Afg3l2−/− MEFs, 
to a higher extent. The trigger for OMA1 activation in SCA28 
and SPAX5 cells was not a drop of ΔΨm, which we verified 
conserved in patient cells and we previously found unaltered in 
Afg3l2−/− MEFs.10 Our data indicate that the primary stressor 
regulating OMA1 activation in SCA28 is the accumulation of 
mitochondria-encoded polypeptides. Several reports indicate 
that m-AAA proteases are important for preventing an overac-
cumulation of mitochondria-encoded polypeptides.33–35 Data 
form pulse-chase experiments indeed revealed the stabilisation 
of specific mitochondrial translation products in the absence 
of AFG3L2 over time, which correlated with decreased levels 
of OMA1. Chloramphenicol-treatment studies supported this 
mechanism, as we found that this drug stabilises OMA1 levels, 
OPA1 long forms and rescues mitochondrial elongation.
Our data reveal the fine titration of OPA1 turnover likely 
depends on the residual amount of functional m-AAA complexes. 
In SCA28 cells and AFG3L2+/− HEK 293 T cells, where there is 
at least 50% of residual functional m-AAA, there was no accu-
mulation of short forms despite OPA1 processing being accel-
erated. In this context, it seems likely that other proteases in 
the intermembrane space may be working efficiently to prevent 
accumulation of soluble OPA1 short forms. However, OPA1 
short forms accumulated in Afg3l2−/− MEFs, where residual 
function of m-AAA is below the critical level of 50%, indi-
cating that mitochondria are more severely damaged and overall 
protein quality control is compromised, leading to a slower turn-
over of OPA1 short forms. Together, these data strengthen the 
concept that the amount of OPA1 long forms is the key mediator 
for efficient mitochondrial fusion. Consistent with this finding, 
OPA1+/−cells show increased mitochondrial fragmentation 
despite unaltered OPA1 processing.37 38
Another important finding of this work is that mitochondrial 
calcium uptake is reduced in SCA28 and SPAX5 fibroblasts. We 
had previously shown that primary murine Afg3l2−/− PCs also 
have reduced mitochondrial calcium uptake, leading to disrup-
tion of calcium homeostasis and activation of PC-DCD. This 
mechanism was consistent with previous data where treatment 
with ceftriaxone, a drug capable of blocking calcium influx in 
PCs by reducing glutamatergic stimulation, was effective in 
rescuing the ataxic phenotype of the Afg3l2+/− haploinsufficient 
mice.11 In the current work, we demonstrated similar findings, 
which indicate that ceftriaxone therapy may be beneficial for 
SCA28 or SPAX5 patients.
In conclusion, this study established the physiopathological 
cascade of events in SCA28 primary fibroblasts, which included: 
(1) proteostatic stress as the major trigger for OMA1 activation, 
leading to (2) OPA1 overprocessing, (3) mitochondrial frag-
mentation and (4) decreased calcium buffering (our model is 
Figure 6 Model explaining the pathogenic cascade of events in Sca28 cells. in physiological conditions, the amount of mitochondria-encoded proteins is 
controlled, and OMa1 activity is limited, leading to normal OPa1 processing, efficient mitochondrial fusion and calcium buffering. in condition of decreased 
aFg3l2 activity, there is accumulation of mitochondria-encoded proteins, with proteostatic stress leading to OMa1 hyperactivation and autocatalysis, 
enhanced OPa1 processing, inefficient mitochondrial fusion and decreased calcium buffering. Sca28, spinocerebellar ataxias type 28.
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summarised in figure 6). Because fibroblasts are not the primary 
site of affection in SCA28, future studies in primary neurons 
and preclinical models are required to reconfirm this proposed 
cascade of events and to determine if attenuation of mitochon-
drial synthesis may represent a new translational perspective for 
AFG3L2-associated neurodegeneration.
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